1. Loeffler G, Hurst D, Penn A, Yung K. Spice, bath salts, and the U.S. military: the emergence of synthetic cannabinoid receptor agonists and cathinones in the U.S. armed forces. Mil Med. 2012;177(9):1041-1048.

2. Cottencin O, Rolland B, Karila L. New designer drugs (synthetic cannabinoids and synthetic cathinones): review of literature.Curr Pharm Des. 2014;20(25):4106-4111.

3. Brunt TM, Poortman A, Niesink RJM, van den Brink W. Instability of the ecstasy market and a new kid on the block: mephedrone. J Psychopharmacol. 2011;25(11):1543-1547.

4. Nelson ME, Bryant SM, Aks SE. Emerging drugs of abuse. Emerg Med Clin N Am. 2014;32(1):1-28.

5. American Academy of Family Physicians. 2019 Scientific Assembly Needs Assessment: Substance Use and Misuse. Available at https://www.aafp.org/dam/AAFP/documents/events/fmx/needs/fmx19-na-psy-substance-use-and-misuse.pdf. Last accessed October 26, 2021.

6. Jerry J, Collins G, Streem D. Synthetic legal intoxicating drugs: the emerging "incense" and "bath salt" phenomenon.Cleve Clin J Med. 2012;79(4):258-264.

7. Schifano F, Orsolini L, Papanti GD, Corkery JM. Novel psychoactive substances of interest for psychiatry. World Psychiatry. 2015;14(1):15-26.

8. Liechti ME. Novel psychoactive substances (designer drugs): overview and pharmacology of modulators of monoamine signaling. Swiss Med Wkly. 2015;145:w14043.

9. Watterson LR, Hood L, Sewalia K, et al. The reinforcing and rewarding effects of methylone, a synthetic cathinone commonly found in "bath salts." J Addict Res Ther. 2012;Suppl 9.

10. United Nations Office on Drugs and Crime. UNODC Early Warning Advisory on New Psychoactive Substances. Available at https://www.unodc.org/LSS/Page/NPS. Last accessed October 26, 2021.

11. European Monitoring Centre for Drugs and Drug Addiction. European Drug Report 2021: Trends and Development. Available at https://www.emcdda.europa.eu/system/files/publications/13838/TDAT21001ENN.pdf. accessed November 8, 2021.

12. Guzman AR. United States Encounters and Efforts against Synthetic Designer Drugs. Presentation at the 22nd National Conference on Pharmaceutical and Chemical Diversion. Available at https://www.deadiversion.usdoj.gov/mtgs/drug_chemical/2014/guzman.pdf. Last accessed November 8, 2021.

13. Mycyk MB. Emerging drugs of abuse: what was new yesterday is new today. J Med Toxicol. 2012;8(1):1-2.

14. European Monitoring Centre for Drugs and Drug Addiction. European Drug Report 2018: Trends and Development. Available at https://www.emcdda.europa.eu/system/files/publications/8585/20181816_TDAT18001ENN_PDF.pdf. accessed October 26, 2021.

15. European Monitoring Centre for Drugs and Drug Addiction. European Drug Report 2015. Available at https://www.emcdda.europa.eu/system/files/publications/974/TDAT15001ENN.pdf. Last accessed November 8, 2021.

16. Karila L, Megarbane B, Cottencin O, Lejoyeux M. Synthetic cathinones: a new public health problem. Curr Neuropharmacol. 2015;13(1):12-20.

17. Biliński P, Holownia P, Kapka-Skrzypczak L, Wojtyla A. Designer drug (DD) abuse in Poland: a review of the psychoactive and toxic properties of substances found during seizures of illegal drug products and resulting legal consequences thereof. Part I: cannabinoids and cathinones. Ann Agric Environ Med. 2012;19(4):857-870.

18. Scalzo AJ. Synthetic Drugs: Cannabinoids and Cathinones, Amphetamines, 2C Drugs
Toxicology and Case Studies. Presented at: 2015 Midwest Pediatric Trauma Conference; May 15, 2015; St. Charles, MO.

19. United Way of Broward County Commission on Substance Abuse. Drug Abuse Trends
 in Broward County, Florida Annual Report: June 2015. Available at http://cdn.trustedpartner.com/docs/library/UWBCCommissionSubstanceAbuse2011/Content/Documents/Data%20Central/June%202015%20Broward%20Annual%20Trends%20Report.pdf. Last accessed November 8, 2021.

20. Carpenter TG, Cato Institute. Designer Drugs. A New, Futile Front in the War on Illegal Drugs. Policy Analysis Number 774. Available at https://www.cato.org/sites/cato.org/files/pubs/pdf/pa774_1.pdf. Last accessed November 8, 2021.

21. United Way of Broward County Commission on Substance Abuse. Drug Abuse Trends
in Broward County, Florida Annual Report: June 2017. Available at https://www.unitedwaybroward.org/sites/default/files/images/Commission%20on%20Behavioral%20Health%20%26%20Drug%20Prevention/Prevention%20Resource%20Center/June-2017-Broward-Substance-Abuse-Trends-Report.pdf. Last accessed November 8, 2021.

22. European Monitoring Centre for Drugs and Drug Addiction. New Psychoactive Substances in Europe: An Update from the EU Early Warning System. Available at https://www.emcdda.europa.eu/publications/rapid-communications/2015/new-psychoactive-substances_en. Last November 18, 2021.

23. National Institute of Standards and Technology, U.S. Drug Enforcement Administration. Emerging Trends in Synthetic Drugs Workshop. Available at https://www.nist.gov/news-events/events/2013/04/emerging-trends-synthetic-drugs-workshop. Last accessed November 8, 2021.

24. Weinstein AM, Rosca P, Fattore L, London ED. Synthetic cathinone and cannabinoid designer drugs pose a major risk for public health. Front Psychiatry. 2017;8:156.

25. Boyce N. Novel Psychoactive Substances. Presented at: Third Annual Addictions and Mental Health Conference; May 25, 2015; Ontario. Available at https://www.slideshare.net/OHSUTP/novel-psychoactive-substances-an-analyis-of-the-2015-psa-cookin-with-molly. Last accessed November 8, 2021.

26. Federal Register. Health and Public Welfare. Available at https://www.federalregister.gov. Last accessed November 8, 2021.

27. Engebretsen KM. Clinical Professor, University of Minnesota, and President-elect, American Board of Applied Toxicology. Personal communication with the author, September 14, 2015.

28. Howlett AC, Thomas BF, Huffman JW. The spicy story of cannabimimetic indoles. Molecules. 2021;26(6190):1-30.

29. Weinstein AM, Rosca P, Fattore L, London ED. Synthetic cathinone and cannabinoid designer drugs pose a major risk for public health. Front Psychiatry. 2017;8:156.

30. Liu L, Wheeler SE, Venkataramanan, et al. Newly emerging drugs of abuse and their detection methods: an ACLPS critical review. Am J Clin Pathol. 2018;149(2):105-116.

31. NDEWS. National Drug Early Warning System. Available at https://ndews.org. Last accessed November 15, 2021.

32. Trecki J, Gerona RR, Schwartz MD. Synthetic cannabinoid-related illnesses and deaths. N Engl J Med. 2015;373(2):103-107.

33. U.S. Congress. HR.4459: Stop the Importation and Manufacturing of Synthetic Analogues Act of 2021 Available at https://www.congress.gov/bill/117th-congress/house-bill/4459. Last accessed November 14, 2021.

34. Centers for Disease Control and Prevention. Vital Statistics Rapid Release: Provisional Drug Overdose Death Counts. Available at https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm. Last accessed November 13, 2021.

35. Zawilska JB. An expanding world of novel psychoactive substances: opioids. Front Psychiatry. 2017;8:110.

36. American Association of Poison Control Centers. National Poison Data System. Available at https://aapcc.org/national-poison-data-system. Last accessed November 15, 2021.

37. Sacco LN, Finklea K, Congressional Research Service. Synthetic Drugs: Overview and Issues for Congress. Available at https://sgp.fas.org/crs/misc/R42066.pdf. Last accessed November 15, 2021.

38. U.S. Drug Enforcement Administration. National Drug Threat Assessment, 2020. Available at https://cesar.umd.edu/sites/cesar.umd.edu/files/pubs/DEA-Emerging-Threat-Report-2020-Annual.pdf. Last accessed November 14, 2021.

39. Schulenberg JE, Patrick ME, Johnston LD, et al. Monitoring the Future National Survey Results on Drug Use, 1975–2020: Volume II, College Students and Adults Ages 19–60. Available at http://www.monitoringthefuture.org/pubs/monographs/mtf-vol2_2020.pdf. Last accessed November 15, 2021.

40. University of Maryland Center for Substance Abuse Research. CESAR FAX Synthetic Cannabinoid Series May 9, 2011 to October 12, 2015 (updated October 13, 2015). Available at http://www.cesar.umd.edu/cesar/pubs/SyntheticCannabinoidCESARFAX.pdf. Last accessed November 15, 2021.

41. Berry-Cabán CS, Kleinschmidt PE, Rao DS, Jenkins J. Synthetic cannabinoid and cathinone use among U.S. soldiers. US Army Med Dep J. 2012;Oct-Dec:19-24.

42. Gardiner R. Banning Raves in California Won't Save Lives. Available at https://mixmag.net/feature/banning-raves-in-california-wont-save-lives. Last accessed November 16, 2021.

43. Coppola M, Mondola R. Synthetic cathinones: chemistry, pharmacology and toxicology of a new class of designer drugs of abuse marketed as "bath salts" or "plant food." Toxicol Lett. 2012;211(2):144-149.

44. Valeriani G, Corazza O, Bersani FS, et al. Olanzapine as the ideal "trip terminator"? Analysis of online reports relating to antipsychotics' use and misuse following occurrence of novel psychoactive substance-related psychotic symptoms. Hum Psychopharmacol. 2015;30(4):249-254.

45. Moore K, Dargan PI, Wood DM, Measham F. Do novel psychoactive substances displace established club drugs, supplement them or act as drugs of initiation? The relationship between mephedrone, ecstasy and cocaine. Eur Addict Res. 2013;19(5): 276-282.

46. Hohmann N, Mikus G, Czock D. Effects and risks associated with novel psychoactive substances: mislabeling and sale as bath salts, spice, and research chemicals. Dtsch Arztebl Int. 2014;111(9):139-147.

47. United Nations Office on Drugs and Crime. World Drug Report 2021. Available at https://www.unodc.org/unodc/en/data-and-analysis/wdr2021.html. Last accessed November 16, 2021.

48. Baumeister D, Tojo LM, Tracy DK. Legal highs: staying on top of the flood of novel psychoactive substances. Ther Adv Psychopharmacol. 2015;5(2):97-132.

49. United Nations Office on Drugs and Crime. Recommended Methods for the Identification and Analysis of Amphetamine, Methamphetamine and Their Ring-Substituted Analogues
in Seized Materials. Available at https://www.unodc.org/pdf/scientific/stnar34.pdf. Last accessed November 16, 2021.

50. Wilson B, Tavakoli H, DeCecchis D, Mahadev V. Synthetic cannabinoids, synthetic cathinones, and other emerging drugs of abuse. Psychiatr Ann. 2013;43(12):558-564.

51. U.S. Drug Enforcement Administration. 4-Bromo-2,5-dimethoxyphenethylamine. Available at https://www.deadiversion.usdoj.gov/drug_chem_info/bromo_dmp.pdf. Last accessed November 17, 2021.

52. U.S. Drug Enforcement Administration. 2C-I, 4-Iodo-2,5-dimethoxyphenethylamine. Available at https://www.deadiversion.usdoj.gov/drug_chem_info/2c_i.pdf. Last accessed November 17, 2021.

53. U.S. Drug Enforcement Administration. 2,5-Dimethoxy-4-(n)-propylthiophenethylamine. Available at https://www.deadiversion.usdoj.gov/drug_chem_info/2ct7.pdf. Last accessed November 17, 2021.

54. National Alliance for Model State Drug Laws. Novel Psychoactive Substances and Analogues: Summary of State Laws. Available at https://namsdl.org/wp-content/uploads/Novel-Psychoactive-Substances-and-Analogues-Summary-of-State-Laws.pdf. Last accessed November 21, 2021.

55. Dean BV, Stellpflug SJ, Burnett AM, Engebretsen KM. 2C or not 2C: phenethylamine designer drug review. J Med Toxicol. 2013;9(2):172-178.

56. Advisory Council on the Misuse of Drugs. NBOMe Compounds: A Review of the Evidence of Use and Harm. Available at https://www.gov.uk/government/publications/nbome-compounds-a-review-of-the-evidence-of-use-and-harm. Last accessed November 15, 2021.

57. U.S. Drug Enforcement Administration. 25-NBOMe. 25I-NBOMe, 25C-NBOMe, and 25B-NBOMe. Available at http://www.deadiversion.usdoj.gov/drug_chem_info/nbome.pdf. Last accessed November 15, 2021.

58. Erowid E, Erowid F. LSD Field Tests Differentiate LSD from 25I-NBOMe. Available at https://www.erowid.org/chemicals/lsd/lsd_testing3.shtml. Last accessed November 17, 2021.

59. Ninnemann A, Stuart GL. The NBOMe series: a novel, dangerous group of hallucinogenic drugs. J Stud Alcohol Drugs. 2013;74(6):977-978.

60. Hill SL, Doris T, Gurung S, et al. Severe clinical toxicity associated with analytically confirmed recreational use of 25I-NBOMe: case series. Clin Toxicol. 2013;51(6)487-492.

61. Weaver MF, Hopper JA, Gunderson EW. Designer drugs 2015: assessment and management. Addict Sci Clin Pract. 2015;10:8.

62. Advisory Council on the Misuse of Drugs. Benzofurans: A Review of the Evidence of Use and Harm. Available at https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/261783/Benzofuran_compounds_report.pdf. Last accessed November 17, 2018.

63. Corazza O, Schifano F, Farre M, et al. Designer drugs on the Internet: a phenomenon out-of-control? Analysis of anecdotal online reports relating to the hallucinogenic drug Bromo-Dragonfly. Curr Clin Pharmacol. 2011;6(2):125-129.

64. Biliński P, Holownia P, Kapka-Skrzypczak L, Wojtyla A. Designer drug (DD) abuse in Poland: a review of the psychoactive and toxic properties of substances found during seizures of illegal drug products and resulting legal consequences thereof. Part II: piperazines/piperidines, phenylethylamines, tryptamines and miscellaneous "others." Ann Agric Environ Med. 2012;19(4): 871-882.

65. Sainsbury PD, Kicman AT, Archer RP, King LA, Braithwaite RA. Aminoindanes: the next wave of "legal highs?" Drug Test Anal. 2011;3(7-8):479-482.

66. Nichols DE, Johnson MP, Oberlender R. 5-Iodo-2-aminoindan, a nonneurotoxic analogue of p-iodoamphetamine. Pharmacol Biochem Behav. 1991;38(1):135-139.

67. Rudnick G, Wall SC. Non-neurotoxic amphetamine derivatives release serotonin through serotonin transporters. Mol Pharmacol. 1993;43(2):271-276.

68. Graham JM, Coughenour LL, Barr BM, Rock DL, Nikam SS. 1-Aminoindanes as novel motif with potential atypical antipsychotic properties. Bioorg Med Chem Lett. 2008;18(2):489-493.

69. Iversen L, Gibbons S, Treble R, Setola V, Huang XP, Roth BL. Neurochemical profiles of some novel psychoactive substances. Eur J Pharmacol. 2013;700(1-3):147-151.

70. United Nations Office on Drugs and Crime. Details for Aminoindanes. Available at https://www.unodc.org/LSS/SubstanceGroup/Details/8fd64573-c567-4734-a258-76d1d95dca25. Last accessed November 15, 2021.

71. Sitte HH, Freissmuth M. Amphetamines, new psychoactive drugs and the monoamine transporter cycle. Trends Pharmacol Sci. 2015;36(1):41-51.

72. Cozzi NV, Sievert MK, Shulgin AT, Jacob P 3rd, Ruoho AE. Inhibition of plasma membrane monoamine transporters by beta-ketoamphetamines. Eur J Pharmacol. 1999;381(1):63-69.

73. Prosser JM, Nelson LS. The toxicology of bath salts: a review of synthetic cathinones. J Med Toxicol. 2012;8(1):33-42.

74. Baumann MH, Partilla JS, Lehner KR. Psychoactive "bath salts:" not so soothing. Eur J Pharmacol. 2013;698(1-3):1-5.

75. Baumann MH, Ayestas MA Jr, Partilla JS, et al. The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue. Neuropsychopharmacology. 2012;(5)37:1192-1203.

76. Rothman RB, Baumann MH. Monoamine transporters and psychostimulant drugs. Eur J Pharmacol. 2003;479(1-3):23-40.

77. Murray BL, Murphy CM, Beuhler MC. Death following recreational use of designer drug "bath salts" containing 3,4-methylenedioxypyrovalerone (MDPV). J Med Toxicol. 2012;8(1):69-75.

78. National Alliance for Model State Drug Laws. An Introduction to Synthetic Drugs. Available at https://namsdl.org/wp-content/uploads/An-Introduction-to-Synthetic-Drugs.pdf. Last accessed November 18, 2021.

79. Watterson LR, Kufahl PR, Nemirovsky NE, et al. Potent rewarding and reinforcing effects of the synthetic cathinone 3,4-methylenedioxypyrovalerone (MDPV). Addict Biol. 2014;19(2):165-174.

80. Capriola M. Synthetic cathinone abuse. Clin Pharmacol. 2013;5:109-115.

81. Paillet-Loilier M, Cesbron A, Le Boisselier R, Bourgine J, Debruyne D. Emerging drugs of abuse: current perspectives on substituted cathinones. Subst Abuse Rehabil. 2014;5:37-52.

82. Advisory Council on the Misuse of Drugs. ACMD Report on the Consideration of the Cathinones. Available at https://www.gov.uk/government/publications/acmd-report-on-the-consideration-of-the-cathinones. Last accessed November 18, 2021.

83. Simmler LD, Buser TA, Donzelli M, et al. Pharmacological characterization of designer cathinones in vitro. Br J Pharmacol. 2013;168(2):458-470.

84. Saha K, Partilla JS, Lehner KR, et al. Second-generation mephedrone analogs, 4-MEC and 4-MePPP, differentially affect monoamine transporter function. Neuropsychopharmacology. 2015;40(6):1321-1331.

85. Rickli A, Hoener MC, Liechti ME. Monoamine transporter and receptor interaction profiles of novel psychoactive substances: para-halogenated amphetamines and pyrovalerone cathinones. Eur Neuropsychopharmacol. 2015;25(3):365-376.

86. European Monitoring Centre for Drugs and Drug Addiction. Synthetic Cathinones Drug Profile. Available at http://www.emcdda.europa.eu/publications/drug-profiles/synthetic-cathinones. Last accessed November 18, 2021.

87. U.S. Drug Enforcement Administration. 4-Methylmethcathinone (Mephedrone). Available at http://www.deadiversion.usdoj.gov/drug_chem_info/mephedrone.pdf. Last accessed November 17, 2021.

88. Angoa-Pérez M, Kane MJ, Briggs DI, et al. Mephedrone does not damage dopamine nerve endings of the striatum but enhances the neurotoxicity of methamphetamine, amphetamine and MDMA. J Neurochem. 2013;125(1):102-110.

89. National Alliance for Model State Drug Laws. Novel Psychoactive Substances and Analogues: 2017 Legislative Session Bill Status Update. Available at http://namsdl.dynamicwebware.com/News%20Tab/Highlighted%20Issues/NPS%20and%20Analogues%202017%20Bill%20Status%20Update.pdf. Last accessed November 14, 2021.

90. U.S. Drug Enforcement Administration. 3,4-Methylenedioxypyrovalerone (MDPV). Available at https://www.deadiversion.usdoj.gov/drug_chem_info/mdpv.pdf. Last accessed November 21, 2021.

91. DanceSafe. Available at https://dancesafe.org. Last accessed November 20, 2021.

92. Winstock AR, Mitcheson LR, Deluca P, et al. Mephedrone, new kid for the chop? Addiction. 2011;106(1):154-161.

93. Keary CJ, Nejad SH, Rasimas JJ, Stern TA. Intoxications associated with agitation, tachycardia, hypertension, and fever: differential diagnosis, evaluation, and management. Prim Care Companion CNS Disord. 2013;15(3).

94. Ross EA, Reisfield GM, Watson MC, Chronister CW, Goldberger BA. Psychoactive "bath salts" intoxication with methylenedioxypyrovalerone. Am J Med. 2012;125(9):854-858.

95. Penders TM, Gestring RE, Vilensky DA. Intoxication delirium following use of synthetic cathinone derivatives. Am J Drug Alcohol Abuse. 2012;38(6):616-617.

96. Goshgarian AM, Benford DM, Caplan JP. Bath salt abuse: neuropsychiatric effects of cathinone derivatives. Psychosomatics. 2011;52(6):593-594.

97. Goodnough A, Zezima K. An Alarming New Stimulant, Legal in Many States. Available at https://www.nytimes.com/2011/07/17/us/17salts.html?_r=0. Last accessed November 17, 2021.

98. Spiller HA, Ryan ML, Weston RG, Jansen J. Clinical experience with and analytical confirmation of "bath salts" and "legal highs" (synthetic cathinones) in the United States. Clin Toxicol (Phila). 2011;49(6):499-505.

99. Adebamiro A, Perazella MA. Recurrent acute kidney injury following bath salts intoxication. Am J Kidney Dis. 2012;59(2):273-275.

100. Borek HA, Holstege CP. Hyperthermia and multiorgan failure after abuse of "bath salts" containing 3,4-methylenedioxypyrovalerone. Ann Emerg Med. 2012;60(1):103-105.

101. National Institute on Drug Abuse. Synthetic Cathinones ("Bath Salts") DrugFacts. Available at https://www.drugabuse.gov/publications/drugfacts/synthetic-cathinones-bath-salts. Last accessed November 17, 2021.

102. Papanti D, Orsolini L, Francesconi G, Schifano F. "Noids" in a nutshell: everything you (don't) want to know about synthetic cannabimimetics. Adv Dual Diagn. 2014;7(3):137-148.

103. European Monitoring Centre for Drugs and Drug Addiction. Understanding the "Spice" Phenomenon. Available at https://www.emcdda.europa.eu/publications/thematic-papers/understanding-spice-phenomenon_en. Last accessed November 18, 2021.

104. European Monitoring Centre for Drugs and Drug Addiction. Synthetic Cannabinoids and "Spice" Drug Profile. Available athttps://www.emcdda.europa.eu/publications/drug-profiles/synthetic-cannabinoids. Last accessed November 18, 2021.

105. Huffman JW. CB2 receptor ligands. Mini Rev Med Chem. 2005;5(7):641-649.

106. Goss C. Treatment considerations for patients using so-called legal recreational drugs. JEMS. 2015;40(7):1-12.

107. Sullivan JW. New Drugs of Abuse. Available at http://www.upstate.edu/poison/pdf/community/synthetic_drugs_sullivan.pdf. Last accessed November 18, 2021.

108. Spaderna M, Addy PH, D'Souza DC. Spicing things up: synthetic cannabinoids. Psychopharmacology (Berl). 2013;228(4):525-540.

109. Hurst D, Loeffler G, McLay R. Psychosis associated with synthetic cannabinoid agonists: a case series. Am J Psychiatry. 2011;168(10):1119.

110. van Amsterdam J, Brunt T, van den Brink W. The adverse health effects of synthetic cannabinoids with emphasis on psychosis-like effects. J Psychopharmacol. 2015;29(3):254-263.

111. Gatch MB, Forster MJ, Janowsky A, Eshleman AJ. Abuse liability profile of three substituted tryptamines. J Pharmacol Exp Ther. 2011;338(1):280-289.

112. Tittarelli R, Mannocchi G, Pantano F, Romolo FS. Recreational use, analysis and toxicity of tryptamines. Curr Neuropharmacol. 2015;13(1):26-46.

113. U.S. Drug Enforcement Administration. 5-Methoxy-N,N-diisopropyltryptamine. Available at https://www.deadiversion.usdoj.gov/drug_chem_info/5meodipt.pdf. Last accessed November 18, 2021.

114. Carroll FI, Lewin AH, Mascarella SW, Seltzman HH, Reddy PA. Designer drugs: a medicinal chemistry perspective. Ann N Y Acad Sci. 2012;1248:18-38.

115. European Monitoring Centre for Drugs and Drug Addiction. Europol Joint Report on a New Psychoactive Substance: Methoxetamine (2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone). Available at https://www.emcdda.europa.eu/publications/joint-report/methoxetamine. Last accessed November 18, 2021.

116. Coppola M, Mondola R. Methoxetamine: from drug of abuse to rapid-acting antidepressant. Med Hypotheses. 2012;79(4):504-507.

117. Kjellgren A, Jonsson K. Methoxetamine (MXE): a phenomenological study of experiences induced by a "legal high" from the Internet. J Psychoactive Drugs. 2013;45(3):276-286.

118. Elliott SP, Brandt SD, Wallach J, Morris H, Kavanagh PV. First reported fatalities associated with the "research chemical" 2-methoxydiphenidine. J Anal Toxicol. 2015;39(4):287-293.

119. Lynch K, American Association for Clinical Chemistry. Drug Testing: the Moving Target. Available at https://www.aacc.org/~/media/files/meetings-and-events/resources-from-past-events/conferences/2015/profprac/slides-and-handouts/designerdrugs_handouts_lynch.pdf?la=en. Last accessed November 18, 2021.

120. U.S. Drug Enforcement Administration. Khat. Available at https://www.dea.gov/factsheets/khat. Last accessed November 18, 2021.

121. Johnson MW, MacLean KA, Reissig CJ, Prisinzano TE, Griffiths RR. Human psychopharmacology and dose-effects of salvinorin A, a kappa-opioid agonist hallucinogen present in the plant Salvia divinorum. Drug Alcohol Depend. 2011;115(1-2):150-155.

122. U.S. Drug Enforcement Administration. Salvia divinorum and Salvinorin A. Available at https://www.deadiversion.usdoj.gov/drug_chem_info/salvia_d.pdf. Last accessed November 18, 2021.

123. Addy PH, Garcia-Romeu A, Metzger M, Wade J. The subjective experience of acute, experimentally-induced Salvia divinorum inebration. J Psychopharmacol. 2015;29(4):426-435.

124. U.S. Drug Enforcement Administration. Kratom (Mitragyna speciosa korth). Available at https://www.deadiversion.usdoj.gov/drug_chem_info/kratom.pdf. Last accessed November 18, 2021.

125. Vilke GM, Bozeman WP, Dawes DM, Demers G, Wilson MP. Excited delirium syndrome (ExDS): treatment options and considerations. J Forensic Leg Med. 2012;19(3):117-121.

126. American College of Emergency Physicians, ACEP Excited Delirium Task Force. White Paper Report on Excited Delirium Syndrome. Available at https://www.prisonlegalnews.org/media/publications/acep_report_on_excited_delirium_syndrome_sept_2009.pdf. Last accessed November 18, 2021.

127. Penders TM, Gestring RE, Vilensky DA. Excited delirium following use of synthetic cathinones (bath salts). Gen Hosp Psychiatry. 2012;34(6):647-650.

128. Karch SB. Cathinone neurotoxicity ("the "3Ms"). Curr Neuropharmacol. 2015;13(1):21-25.

129. Takeuchi AT, Ahern TL, Henderson SO. Excited delirium. West J Emerg Med. 2011;12(1):77-83.

130. Mash D, Duque L, Pablo J, et al. Brain biomarkers for identifying excited delirium as a cause of sudden death. Forensic Sci Int. 2009;190(1-3):e13-e19.

131. Lusthof KJ, Oosting R, Maes A, Verschraagen M, Dijkhuizen A, Sprong AG. A case of extreme agitation and death after the use of mephedrone in the Netherlands. Forensic Sci Int. 2011;206(1-3):e93-e95.

132. Scheppke KA, Braghiroli J, Shalaby M, Chait R. Prehospital use of IM ketamine for sedation of violent and agitated patients.West J Emerg Med. 2014;15(7):736-741.

133. Keseg D, Cortez E, Rund D, Caterino J. The use of prehospital ketamine for control of agitation in a metropolitan firefighter-based EMS system. Prehosp Emerg Care. 2015;19(1):110-115.

134. Burnett AM, Peterson BK, Stellpflug SJ, et al. The association between ketamine given for prehospital chemical restraint with intubation and hospital admission. Am J Emerg Med. 2015;33(1):76-79.

135. Burnett AM, Salzman JG, Griffith KR, Kroeger B, Frascone RJ. The emergency department experience with prehospital ketamine: a case series of 13 patients. Prehosp Emerg Care. 2012;16(4):553-559.

136. van Loggerenberg CJ. Emergency management of drug abuse in South Africa. S Afr Med J. 2012;30(11):409-412.

137. Addolorato G, Leggio L, Abenavoli L, Gasbarrini G, Alcoholism Treatment Study Group. Neurobiochemical and clinical aspects of craving in alcohol addiction: a review. Addict Behav. 2005;30(6):1209-1224.

138. Clapp P, Bhave SV, Hoffman PL. How adaptation of the brain to alcohol leads to dependence: a pharmacological perspective. Alcohol Res Health. 2008;31(4):310-339.

139. Baguley IJ, Heriseanu RE, Cameron ID, Nott MT, Slewa-Younan S. A critical review of the pathophysiology of dysautonomia following traumatic brain injury. Neurocrit Care. 2008;8(2):293-300.

140. Baguley IJ, Heriseanu RE, Nott MT, Chapman J, Sandanam J. Dysautonomia after severe traumatic brain injury: evidence of persisting overresponsiveness to afferent stimuli. Am J Phys Med Rehabil. 2009;88(8):615-622.

141. Srinivasan S, Tchoyoson Lim CC, Thirugnanam U. Paroxysmal autonomic instability with dystonia. Clin Auton Res. 2007;17(6):378-381.

142. Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest. 2009;136(5 Suppl):e28.

143. Dalmau J, Tüzün E, Wu HY, et al. Paraneoplastic anti-N-methyl-d-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol. 2007;61(1):25-36.

144. Fink M, Taylor MA. The many varieties of catatonia. Eur Arch Psychiatry Clin Neurosci. 2001;251(Suppl 1):I8-I13.

145. Iqbal MM, Basil MJ, Kaplan J, Iqbal T. Overview of serotonin syndrome. Ann Clin Psychiatry. 2012;24(4):310-318.

146. Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005;352:1112-1120.

147. Gold JA, Rimal B, Nolan A, Nelson LS. A strategy of escalating doses of benzodiazepines and phenobarbital administration reduces the need for mechanical ventilation in delirium tremens. Crit Care Med. 2007;35(3):724-730.

148. Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM. 2003;96(9):635-642.

149. Prator BC. Serotonin syndrome. J Neurosci Nurs. 2006;38(2):102-105.

150. Carhart-Harris RL, King LA, Nutt DJ. A web-based survey on mephedrone. Drug Alcohol Depend. 2011;118(1):19-22.

151. Dargan PI, Albert S, Wood DM. Mephedrone use and associated adverse effects in school and college/university students before the UK legislation change. QJM. 2010;103(11):875-879.

152. Winstock A, Mitcheson L, Ramsey J, Davies S, Puchnarewicz M, Marsden J. Mephedrone: use, subjective effects and health risks. Addiction. 2011;106(11):1991-1996.

153. Coppola M, Mondola R. 3,4-methylenedioxypyrovalerone (MDPV): chemistry, pharmacology and toxicology of a new designer drug of abuse marketed online. Toxicol Lett. 2012;208(1):12-15.

154. Zimmermann US, Winkelmann PR, Pilhatsch M, et al. Withdrawal phenomena and dependence syndrome after the consumption of "spice gold." Dtsch Arztebl Int. 2009;106(27):464-467.

155. Advisory Council on the Misuse of Drugs. Consideration of the Novel Psychoactive Substances ("Legal Highs"). Available at https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/119139/acmdnps2011.pdf. Last accessed November 21, 2021.

156. Winstock AR, Mitcheson L. New recreational drugs and the primary care approach to patients who use them. BMJ. 2012;344:e288.

157. Karila L, Weinstein A, Aubin HJ, Benyamina A, Reynaud M, Batki SL. Pharmacological approaches to methamphetamine dependence: a focused review. Br J Clin Pharmacol. 2010;69(6):578-592.

158. Rose ME, Grant JE. Pharmacotherapy for methamphetamine dependence: a review of the pathophysiology of methamphetamine addiction and the theoretical basis and efficacy of pharmacotherapeutic interventions. Ann Clin Psychiatry. 2008;20(3):145-155.

159. U.S. Drug Enforcement Administration. DEA Announces Intent to Schedule Kratom. Available at https://www.dea.gov/press-releases/2016/08/30/dea-announces-intent-schedule-kratom. Last accessed November 18, 2021.

160. Wright TH, Harris C. Twenty-One Cases Involving Alpha-Pyrrolidinoyalerophenone (α-PVP). J Anal Toxicol. 2016;40(5):396-402.

161. U.S. Drug Enforcement Administration. About Synthetic Drugs. Available at https://www.deadiversion.usdoj.gov/synthetic_drugs/about_sd.html. Last accessed November 8, 2021.

162. M Haden, D M Wood, P I Dargan. The impact of the Psychoactive Substances Act 2016 on the online availability of MDMB-CHMICA. QJM. 2017;110(10):619-622.

163. Majchrzak M, Celiński R, Kuś P, et al. The newest cathinone derivatives as designer drugs: an analytical and toxicological review. Forensic Toxicol. 2018;36(1):33-50.